A PYMNTS Company

US: Lipitor pay-for-delay case on appeal

By  |  January 7, 2016

In In re Lipitor Antitrust Litigation, Judge Sheridan (District of New Jersey) found that the notion of “payment” in drug patent settlements extends beyond cash transfers to include non-cash conveyances. But the court required such a conveyance to be “converted to a reliable estimate of its monetary value” and ruled that non-cash deals should clear a heightened plausibility standard. The court also introduced a new test that was based on the False Claims Act and that significantly raised the bar facing plaintiffs.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    In a brief filed last week on behalf of 48 professors and the American Antitrust Institute, Professor Michael Carrier and Steve Shadowen call on the Third Circuit to reverse this decision. They contend that the opinion undermines the Supreme Court’s ruling in FTC v. Actavis, the Third Circuit’s Lamictal decision, and pleading requirements articulated in Supreme Court and Third Circuit precedents. The brief also highlights allegations that typically survive a motion to dismiss, most notably the brand firm’s forgiveness of hundreds of millions of dollars facing the generic in separate litigation.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    The Third Circuit will consider this case together with an earlier-filed appeal in the In re Effexor case, which also involved heightened pleading standards, in this case applied to a “no-authorized-generic” promise by which a brand promises not to introduce its own generic that would compete with the “true” generic.

    Full content attached: Lipitor amicus brief 48 profs AAI

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.